Dette var helt som forventet og tidligere kommunisert. Alle biotek med indikasjoner med pasienter er per nu jobber med inklusjon og kostnadsbildet etter COVID 19.
Når det gjelder COVID 19 og business var dette overraskende med eget avsnitt i Q 4 rapport:
Potential COVID-19 opportunities
Significant efforts are being invested by the global health community to research and develop potential treatments against COVID-19. Most vaccine companies are currently focused on reaching the clinic with their own established technologies and may not be open for the inclusion of new technologies in the short term. PCI Biotech is nevertheless closely monitoring and exploring potential opportunities to contribute to these efforts, as the characteristics of the PCI technology may fit well with the medical needs.»
Klarere kan det ikke sies at PCIB har muligheter nu og ved senere pandemi med sin fimaVacc teknologi!
Fimachem jobbes det godt med i Asia, liten eller ingen påvirkning og regulatorisk godkjennelse!
Site preparations are ongoing for addition of Asian sites in 2020, to provide access to hospitals and KOL’s in a region with higher prevalence of bile duct cancer and to enhance patient recruitment. So far progress has not been significantly impacted by the COVID-19 pandemic and regulatory approval has been achieved in Taiwan.
Fortsatt on track med samtaler AstraZeneca, ingen endring ved timeline!!
« The collaboration agreement with AstraZeneca has been extended several times and the scope of the collaboration was recently expanded to evaluate whether synergies established in oncology in vivo models are transferrable to additional disease areas. The research collaboration ran to the end of 2019 and the companies have agreed to use the following 6 months until end of June 2020 to evaluate the potential for further collaboration.»
Hegnar: PCI Biotech i pluss etter finansinntekter på 21 mill.
Greit at de påpeker de gode resultater i rapporten!
The RELEASE study builds on the favourable safety results and encouraging early signs of efficacy in the Phase I study, with more than 80% of the patients being progression-free at 6 months.
Tumour response translates into encouraging survival data
The RELEASE study builds on the favourable safety results and encouraging early signs of efficacy in the Phase I study, with more than 80% of the patients being progression-free at 6 months.
The fimaCHEM treatment boosts the chemotherapy effect locally in the bile duct. Local tumour response in the bile duct is important to maintain biliary drainage, and the primary tumour response may therefore be more important for survival outcome than would be the case for many other cancers.
All patients have been followed-up for survival post-study and the finally confirmed median overall survival (mOS) for the full study ended on 16.1 months at final censoring, with two patients still being alive.
The group in the dose escalation study that received the RELEASE study dose (n=6, cohort IV) had a mOS of 22.8 months. Three of these patients exceeded 30 months survival, including one patient still alive more than four years after inclusion in the study
:
